IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Provided By GlobeNewswire
Last update: Aug 14, 2025
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today reported financial results and business highlights for the second quarter of 2025.
Read more at globenewswire.com
